Overview

Press Releases & News

Stay informed on the latest breakthroughs, partnerships, and milestones at PGxAI. Our press releases and news updates reflect our ongoing commitment to transforming healthcare through AI-powered precision medicine.

SEARCH BY TITLE

PGxAI and Novo Genomics scale AI‑enabled pharmacogenomics across Saudi Arabia

PGxAI and Novo Genomics are collaborating to enhance AI-enabled pharmacogenomics in Saudi Arabia, aiming to improve personalized prescribing and medication safety. Their initiative includes local lab processing, AI-assisted analysis, and clinician-ready reporting, which will reduce turnaround times and expand access to precision medicine. The partnership aligns with Saudi Arabia's Vision 2030, focusing on training, technology transfer, and research to position the Kingdom as a leader in AI-driven precision medicine. The program emphasizes voluntary patient participation and aims to reduce adverse drug reactions while ensuring equitable access to healthcare.

PGxAI and Novo Genomics are collaborating to scale AI-enabled pharmacogenomics across Saudi Arabia, enabling safer and more personalized prescribing.

The partnership supports medication safety, reduces adverse drug reactions, and expands access to precision medicine in alignment with Saudi Vision 2030.

The initiative emphasizes voluntary, consent-based participation while building in-country expertise and advancing innovation across the Kingdom’s healthcare system.

PGxAI and Mahd Sports Academy announce strategic partnership to advance AI‑enabled sports genomics across Saudi Arabia

PGxAI and Mahd Sports Academy are partnering to bring advanced genetics and AI into athlete development across Saudi Arabia, with the goal of improving personalized training, preventing avoidable injuries, and enhancing overall performance. The collaboration will integrate genetic, phenotypic, and biometric data into secure, coach- and clinician-ready workflows while ensuring all data is stored and retained within the Kingdom under Saudi Arabia’s Personal Data Protection Law. The initiative emphasizes voluntary participation, clear communication of insights, and equitable access for both men’s and women’s sports, while supporting Saudi Vision 2030 through training, technology transfer, and research to strengthen national expertise in sports science and precision performance.

PGxAI and Mahd Sports Academy are partnering to integrate genetics and AI into athlete training and performance development across Saudi Arabia.

The program focuses on personalized training, injury prevention, and safe return-to-play, with voluntary, consent-based participation for athletes.

All data will be stored and retained within Saudi Arabia, aligned with the Personal Data Protection Law (PDPL) and supporting Vision 2030 through localization, training, and research.

PGxAI and Lean Business Services Partner to Scale AI Pharmacogenomics in Saudi Arabia

PGxAI has announced a strategic partnership with Lean Business Services and Najashi Holding to deploy AI-driven pharmacogenomics across Saudi Arabia in support of the Kingdom’s Vision 2030 Health Sector Transformation Program. The initiative aims to establish a fully in-country precision medicine ecosystem, ensuring that genomic data is analyzed, governed, and retained within Saudi borders to strengthen data sovereignty and national security. By integrating AI-powered pharmacogenomic insights directly into clinical workflows and electronic health records, the partnership seeks to reduce preventable adverse drug reactions at population scale and shift Saudi healthcare from reactive treatment to predictive, personalized prescribing.

PGxAI Selected as a Finalist at the HLTH USA 2025 Startup Pitch Tournament

PGxAI has been selected as a finalist in the HLTH USA 2025 Startup Pitch Tournament, highlighting the company’s expanding impact in AI-driven precision medicine.

PGxAI was named a finalist in the HLTH USA 2025 Startup Pitch Tournament in the Specialty Care category, selected from hundreds of applicants.

HLTH USA is one of the world’s largest and most influential healthcare conferences, bringing together leading health systems, payors, researchers, investors, and regulators.

Participation reinforces PGxAI’s growing visibility in precision medicine, highlighting the relevance of our AI and multi-omics technologies for advancing clinical decision-making.

PGxAI and Najashi Holding partner to advance precision medicine in Saudi Arabia

PGxAI has partnered with Riyadh-based Najashi Holding to bring its AI-powered pharmacogenomics platform to Saudi Arabia.

The collaboration supports the Kingdom’s healthcare transformation under Vision 2030, strengthening its position as a global leader in precision medicine.

Najashi Holding, a pioneering regional healthcare investor, is committing equity to PGxAI’s planned $20 million Series A round in 2026.

The company will also mobilize its extensive public- and private-sector networks to accelerate the adoption of personalized care across the country.

PGxAI Welcomes Roni Zeiger as Product Strategy Advisor

PGxAI appoints Roni Zeiger—former Meta Head of Health Strategy, former Google Chief Health Strategist, and co‑founder of Smart Patients—as Product Strategy Advisor to strengthen patient‑centered product development and AI strategy in pharmacogenomics.

Led health strategy at Meta (2019–2023) and Google (2006–2012), bringing large‑scale consumer health product expertise

Co‑founded Smart Patients and scaled patient‑to‑patient learning communities to inform community‑driven product design

17 years of frontline clinical practice; currently advises Added Health, Moneta Health, Noora Health, HERA Digital Health, and Streetwyze on product strategy and AI in health

PGxAI Admitted to Creative Destruction Lab (CDL) Seattle — Computational Health 2025–2026

PGxAI has been admitted to the Creative Destruction Lab (CDL) Seattle 2025–2026 program in the Computational Health stream at the University of Washington’s Foster School of Business.

Admitted to CDL Seattle — Computational Health (2025–2026)

The objectives‑based CDL program pairs founders with experienced operators, scientists, and investors to set measurable milestones and accelerate commercialization.

Focus on health‑system co‑development, measurable clinical‑economic KPIs, and scaled PGx deployment

PGxAI Welcomes John Quackenbush as Scientific Advisor

PGxAI appoints John Quackenbush—Harvard biostatistics chair, White House Open Science honoree, and Genospace co-founder—as Scientific Advisor to strengthen multi-omics analytics, reproducibility, and nationwide interoperability.

Leads Harvard Chan Biostatistics; 350+ publications & >103k citations

White House Open Science Champion of Change 2013; NAM member 2022

Advises PGxAI on scalable multi-omics integration, data standards, and clinical decision support

PGxAI and Sequencing.com Announce Strategic Partnership to Advance Affordable Pharmacogenomics

PGxAI and Sequencing.com formed a strategic partnership to introduce PGx reports on Sequencing.com and advance affordable, safer prescribing through pharmacogenomics.

Strategic partnership with Sequencing.com; PGx reports available via the Sequencing.com marketplace.

Focus on ADR reduction and affordability.

Compatibility with popular consumer genetic data formats; new revenue opportunities for genomic labs.

PGxAI Named a Key Player in Straits Research’s Pharmacogenomics (PGX) Market Report

Straits Research included PGxAI among key players in its Pharmacogenomics (PGX) Market report (2025–2033) and profiled the company as an emerging innovator. The report projects market growth from $6.13B (2024) to $11.17B (2033) at a 6.6% CAGR.

PGxAI listed among key players and profiled in Straits Research’s PGX Market report.

Market outlook: $6.13B (2024) to $11.17B (2033), 6.6% CAGR.

Recognition underscores PGxAI’s AI‑enabled, guideline‑driven approach to safer, more effective prescribing.

PGxAI Welcomes David Blumenthal as Scientific Advisor

PGxAI appoints David Blumenthal, former National Coordinator for Health Information Technology, as Scientific Advisor to guide digital-health strategy and integrate precision-medicine innovations with nationwide health IT infrastructure.

Led the implementation of the HITECH Act’s “meaningful use” program, driving nationwide EHR adoption and health‐IT infrastructure modernization

Brings deep expertise in health policy, government advisory roles, and academic thought leadership on digital‐health interoperability

Advises PGxAI on integrating its precision‐medicine platform with national health IT systems and shaping supportive policy frameworks

Benchmarking LLMs for Pharmacogenomic (PGx) Recommendations

- Evaluated 5 leading LLMs on 599 CPIC‑aligned gene–drug–phenotype scenarios to reproduce guideline‑based PGx recommendations. - Introduced a validated semantic evaluation metric (LLM Score) alongside standard lexical metrics. - A domain‑adapted model reached LLM Score 0.92 with significantly faster inference than general‑purpose models.

General‑purpose models frequently produced incomplete or unsafe outputs; domain adaptation improved clinical completeness and safety.

Minimal fine‑tuning + structured prompting markedly increased accuracy and reduced inference time (orders of magnitude).

Establishes a robust evaluation framework for PGx‑specific LLMs and demonstrates the feasibility of safer, AI‑driven personalized medicine.

AI & Multi-Omics in Pharmacogenomics: PGxAI’s New Review

An open-access review in Mayo Clinic Proceedings: Digital Health shows how AI-enabled integration of genomic, transcriptomic, proteomic and metabolomic data is reframing pharmacogenomics. The paper distills recent breakthroughs, real-world evidence and remaining hurdles on the path to routine precision prescribing.

Multi-omics integration captures drug-response biology that single-gene tests miss

GNN, VAE and LLM architectures demonstrably raise prediction accuracy and clinical decision support

Real-world datasets, explainable AI and federated workflows chart feasible routes to bedside adoption

PGxAI Unveils Betelgeuse — New AI Model for Real-Time Clinical Outcome Analysis and Adaptive Recommendations

Internal server error